BioLife Solutions, Inc. (NASDAQ:BLFS)’s stock price was up 5.9% during mid-day trading on Wednesday . The stock traded as high as $42.96 and last traded at $42.47. Approximately 258,660 shares traded hands during trading, a decline of 19% from the average daily volume of 318,870 shares. The stock had previously closed at $40.11.

Several equities research analysts recently issued reports on BLFS shares. Lake Street Capital lifted their price objective on BioLife Solutions from $29.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, September 22nd. KeyCorp assumed coverage on BioLife Solutions in a research note on Monday, November 9th. They set an “overweight” rating and a $40.00 price target for the company. Cowen assumed coverage on BioLife Solutions in a research note on Friday, September 18th. They set an “outperform” rating and a $33.00 price target for the company. Oppenheimer lowered BioLife Solutions from an “outperform” rating to a “market perform” rating in a research note on Tuesday, September 22nd. Finally, B. Riley lifted their price target on BioLife Solutions from $30.00 to $35.00 in a research note on Monday, October 19th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $32.30.

The business has a 50 day moving average price of $40.25 and a two-hundred day moving average price of $28.49. The company has a market cap of $1.39 billion, a P/E ratio of -58.18, a price-to-earnings-growth ratio of 51.00 and a beta of 1.55.

BioLife Solutions (NASDAQ:BLFS) last released its earnings results on Thursday, November 5th. The medical equipment provider reported ($0.02) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.02). BioLife Solutions had a return on equity of 0.53% and a net margin of 12.67%. The company had revenue of $11.28 million during the quarter, compared to analyst estimates of $10.71 million. Research analysts expect that BioLife Solutions, Inc. will post 0.01 earnings per share for the current fiscal year.

In other BioLife Solutions news, major shareholder Casdin Partners Master Fund, L purchased 1,600,000 shares of BioLife Solutions stock in a transaction that occurred on Tuesday, November 24th. The shares were bought at an average price of $22.50 per share, for a total transaction of $36,000,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Walter Villiger sold 80,000 shares of the business’s stock in a transaction dated Monday, January 11th. The shares were sold at an average price of $40.24, for a total value of $3,219,200.00. The disclosure for this sale can be found here. In the last three months, insiders sold 868,168 shares of company stock valued at $27,980,454. 22.30% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA increased its holdings in BioLife Solutions by 1,358.5% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 2,990 shares of the medical equipment provider’s stock valued at $87,000 after purchasing an additional 2,785 shares during the period. Ardsley Advisory Partners LP purchased a new position in BioLife Solutions during the 3rd quarter valued at about $217,000. The Manufacturers Life Insurance Company purchased a new position in shares of BioLife Solutions during the 3rd quarter worth approximately $223,000. American International Group Inc. grew its holdings in shares of BioLife Solutions by 85.0% during the 3rd quarter. American International Group Inc. now owns 8,220 shares of the medical equipment provider’s stock worth $238,000 after acquiring an additional 3,776 shares during the period. Finally, Quantitative Systematic Strategies LLC purchased a new position in shares of BioLife Solutions during the 3rd quarter worth approximately $250,000. Institutional investors own 67.66% of the company’s stock.

BioLife Solutions Company Profile (NASDAQ:BLFS)

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry in North America, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Featured Story: Learning About the VIX – Volatility Index

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.